You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN--(BUSINESS WIRE)--The "Cancer Therapy Related Diarrhea - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Emerging Drugs Chapters This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Emerging Drugs Crofelemer: Napo Pharmaceuticals Crofelemer is a drug that is a chloride channel antagonist and is presently being studied in Phase III of clinical trial. Originally, this compound was owned by Shaman Pharmaceuticals and currently under the development of Napo Pharmaceuticals. Therapeutic Assessment This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as: Major Players There are approx. 2+ key companies which are developing the therapies for Cancer Therapy Related Diarrhea. The companies which have their Cancer Therapy Related Diarrhea drug candidates in the most advanced stage, i.e. phase III include, Napo Pharmaceuticals. Phases This report covers around 2+ products under different phases of clinical development like: Cancer Therapy Related Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as: Products have been categorized under various Molecule types such as: The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs. Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs. Key Topics Covered: Introduction Executive Summary Cancer Therapy Related Diarrhea: Overview Pipeline Therapeutics Therapeutic Assessment Cancer Therapy Related Diarrhea - Analytical Perspective In-depth Commercial Assessment Cancer Therapy Related Diarrhea Collaboration Deals Late Stage Products (Phase III) Crofelemer: Napo Pharmaceuticals Mid Stage Products (Phase II) Drug Name: Company Name Early Stage Products (Phase I) Drug Name: Company Name Pre-clinical and Discovery Stage Products Drug Name: Company Name Inactive Products Cancer Therapy Related Diarrhea Key Companies Cancer Therapy Related Diarrhea Key Products Cancer Therapy Related Diarrhea- Unmet Needs Cancer Therapy Related Diarrhea- Market Drivers and Barriers Cancer Therapy Related Diarrhea- Future Perspectives and Conclusion Cancer Therapy Related Diarrhea Analyst Views Cancer Therapy Related Diarrhea Key Companies For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x7k6rj

Answer: Global Cancer Therapy Related Diarrhea: 2020 Pipeline Insight Report - ResearchAndMarkets.com